China Meheco Co Ltd - Asset Resilience Ratio
China Meheco Co Ltd (600056) has an Asset Resilience Ratio of 0.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600056 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2024)
This chart shows how China Meheco Co Ltd's Asset Resilience Ratio has changed over time. See 600056 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down China Meheco Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see China Meheco Co Ltd (600056) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥128.73 Million | 0.35% |
| Total Liquid Assets | CN¥128.73 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: China Meheco Co Ltd maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
China Meheco Co Ltd Industry Peers by Asset Resilience Ratio
Compare China Meheco Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.44% |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332 |
Medical Distribution | 5.56% |
Annual Asset Resilience Ratio for China Meheco Co Ltd (1997–2024)
The table below shows the annual Asset Resilience Ratio data for China Meheco Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.36% | CN¥128.73 Million ≈ $18.84 Million |
CN¥35.28 Billion ≈ $5.16 Billion |
+0.32pp |
| 2020-12-31 | 0.05% | CN¥16.32 Million ≈ $2.39 Million |
CN¥33.19 Billion ≈ $4.86 Billion |
-0.52pp |
| 2019-12-31 | 0.57% | CN¥169.27 Million ≈ $24.77 Million |
CN¥29.83 Billion ≈ $4.37 Billion |
-3.73pp |
| 2006-12-31 | 4.30% | CN¥74.29 Million ≈ $10.87 Million |
CN¥1.73 Billion ≈ $252.78 Million |
-3.52pp |
| 2005-12-31 | 7.82% | CN¥130.89 Million ≈ $19.15 Million |
CN¥1.67 Billion ≈ $244.94 Million |
-4.15pp |
| 2004-12-31 | 11.97% | CN¥116.15 Million ≈ $17.00 Million |
CN¥970.44 Million ≈ $142.01 Million |
+11.81pp |
| 2003-12-31 | 0.16% | CN¥1.43 Million ≈ $209.49K |
CN¥920.77 Million ≈ $134.74 Million |
-9.57pp |
| 2002-12-31 | 9.72% | CN¥97.40 Million ≈ $14.25 Million |
CN¥1.00 Billion ≈ $146.59 Million |
-6.87pp |
| 2001-12-31 | 16.59% | CN¥200.00 Million ≈ $29.27 Million |
CN¥1.21 Billion ≈ $176.37 Million |
-15.06pp |
| 2000-12-31 | 31.65% | CN¥355.02 Million ≈ $51.95 Million |
CN¥1.12 Billion ≈ $164.12 Million |
+20.48pp |
| 1998-12-31 | 11.17% | CN¥86.28 Million ≈ $12.63 Million |
CN¥772.11 Million ≈ $112.98 Million |
+4.55pp |
| 1997-12-31 | 6.62% | CN¥50.00 Million ≈ $7.32 Million |
CN¥755.14 Million ≈ $110.50 Million |
-- |
About China Meheco Co Ltd
China Meheco Group Co., Ltd. engages in the manufacture, marketing, and trade of pharmaceuticals and medical devices in China and internationally. The company is involved in the planting and sale of Chinese medicinal materials, as well as the provision of related technical and warehousing services. Its drug products cover therapeutic fields, such as anti-infection, cardiovascular, hormones and en… Read more